Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer

Abstract Background The very aggressive nature and low survival rate of pancreatic ductal adenocarcinoma (PDAC) dictates the necessity to find novel efficacious therapies. Recent evidence suggests that phosphoinositide 3-kinase (PI3K) and 3-phosphoinositide-dependent protein kinase 1 (PDK1) are key...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Aikaterini Emmanouilidi, Chanse A. Fyffe, Riccardo Ferro, Charlotte E. Edling, Emily Capone, Simona Sestito, Simona Rapposelli, Rossano Lattanzio, Stefano Iacobelli, Gianluca Sala, Tania Maffucci, Marco Falasca
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2019-05-01
coleção:	Journal of Experimental & Clinical Cancer Research
Assuntos:	Pancreatic ductal adenocarcinoma Signal transduction Targeted therapy Phosphoinositide 3-kinase 3-phosphoinositide-dependent protein kinase 1 Serum/glucocorticoid regulated kinase family member 3
Acesso em linha:	http://link.springer.com/article/10.1186/s13046-019-1191-2
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!